Publications

View and download slide summaries of the latest original articles focusing on therapies in immune-mediated inflammatory diseases including rheumatology, dermatology, and gastroenterology. All materials produced by the team are subsequently reviewed and approved by individual Steering Committee members.

November 2023

Traitement au bimékizumab chez les patients atteints de spondylarthrite axiale active: efficacité et innocuité à 52 semaines des études randomisées et parallèles de phase 3 BE MOBILE 1 et BE MOBILE 2

Ann Rheum Dis. 2023;83(2):199–213 doi 10.1136/ard-2023-224803

Xu H,

Vaux T,

Baraliakos, et al. present data from two Phase 3 studies, BE MOBILE 1 and BE MOBILE 2, that investigated the clinical efficacy and safety of bimekizumab in axSpA patients. They found that bimekizumab had sustained and consistent efficacy in patients with nr-axSpA and r-axSpA.

Keywords:

October 2023

Otilimab anti-GM-CSF versus Sarilumab ou placebo chez des patients atteints de polyarthrite rhumatoïde et avec une réponse inadéquate aux thérapies ciblées : Un essai randomisé de phase III (contRAst 3)

Ann Rheum Dis. 2023;82(12):1527–1537 doi 10.1136/ard-2023-224449

Goode C,

Gupta A,

Wang M,

Watts S,

Fleischmann R

The ContRAst 3 study investigated otilimab, in RA patients with inadequate responses to multiple treatments. Otilimab did not significantly improve ACR20 versus placebo at Weeks 12 or 24. In addition, there we no significant improvements in secondary endpoints, including disease activity, disability, and pain.

Keywords:

Anti-GM-CSF Otilimab versus Tofacitinib ou placebo chez des patients atteints de polyarthrite rhumatoïde active et présentant une réponse inadéquate aux DMARD conventionnels ou biologiques : Deux essais randomisés de phase 3 (contRAst 1 et contRAst 2)

Ann Rheum Dis 2023;0:1–11 doi 10.1136/ard-2023-224482

Goode C,

Gupta A,

Smith J,

Wang M,

Wang R,

Watts S,

Weinblatt M

Fleischmann, et al investigated the safety and efficacy of otilimab versus tofacitinib and placebo in RA patients treated with MTX (contRAst 1) or csDMARDs (contRAst 2). They found that while otilimab achieved the primary endpoint of ACR20 versus placebo in Week 12, it did not demonstrate non-inferiority to tofacitinib.

Keywords:

February 2023

Efficacité et sécurité du bimekizumab dans la spondylarthrite axiale : Résultats de deux essais contrôlés randomisés de phase 3 menés en parallèle

Ann Rheum Dis. 2023 Jan 17 doi: 10.1136/ard-2022-223595

Vaux T,

Bimekizumab may therefore offer patients with axSpA an effective treatment option with a novel mode of action.

Keywords:

January 2023

Innocuité et efficacité du bimekizumab chez les patients atteints de spondylarthrite ankylosante active : Résultats à trois ans d'un essai contrôlé randomisé de phase IIb et de son étude de prolongation ouverte

Arthritis Rheumatol. 2022;74:1943–58

Molto A,

Vaux T,

In this open-label extension study of BE AGILE, the safety profile of bimekizumab was found to be consistent with previously demonstrated findings, and no new safety signals were identified. The objective was to assess the long-term safety, tolerability, and efficacy of bimekizumab in patients with active AS.